MPNs

The NCCN guidelines for myeloproliferative neoplasms now include ropeginterferon alfa-2b, which was recently granted FDA approval for the treatment of polycythemia vera.

John Mascarenhas, MD, provides advice to oncologists on the use of pacritinib to treatment patients with myelofibrosis and severe thrombocytopenia.

John Mascarenhas, MD, discusses the mechanism of action of pacritinib and how it differs from ruxolitinib and fedratinib.

In an interview with Targeted Oncology, John Mascarenhas, MD, discussed the introduction of pacritinib to the treatment landscape for myelofibrosis and severe thrombocytopenia, and the research supporting the recent FDA approval.

The FDA has approved pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia.

Thromboembolic events and risk of progression continue to affect patients with polycythemia vera, but 2 recent advances may affect the natural course of the disease.

The future of myelofibrosis may include several JAK inhibitor treatment niches as well as combination regimens with JAK inhibition in both the upfront and second-line setting and more, according to John Mascarenhas, MD.

Richard Silver, MD, discusses the Interferon Initiative organized by the Myeloproliferative Neoplasm Research Foundation.

Srdan Verstovsek, MD, discussed maintaining hematocrit levels in patients with polycythemia vera as well as research on the use of rusfertide.

During a Targeted Oncology case-based roundtable event, Ruben Mesa, MD, discussed risk assessment and management of myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD, discusses the main reasons for his study on the use of rusfertide in patients with polycythemia vera.

The MOMENTUM trial of momelotinib showed efficacy in treating symptoms of myelofibrosis, according to a press release.

In an interview with Targeted Oncology, Yelena Ginzburg, MD, discussed the research and use of rusfertide in patients with polycythemia vera.

Results from the ongoing phase 3 MOMENTUM clinical trial may be available by the end of Janaury 2022.

During a Targeted Oncology case-based virtual event, Jamile M. Shammo, MD, discussed testing, risk assessment, and therapy for patients with high-risk myelofibrosis.

With rusfertide, clinical trial investigators are poised to fill a clinical gap by addressing iron deficiency in patients with polycythemia vera.

Richard T. Silver, MD, discusses which patients with myeloproliferative neoplasms may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia space and in patients with myeloproliferative neoplasms.

A phase 2 study is underway to determine the efficacy and safety of selinexor in patients with myelofibrosis.

Full-dose pacritinib beats ruxolitinib in patients with cytopenic myelofibrosis.

Results from the REVEAL study signal link between thrombotic events and white blood cell counts.

The FDA has extended the review period of the new drug application for pacritinib as treatment of patients with myelofibrosis and severe thrombocytopenia.

Carole Miller, MD, discusses the REVEAL trial design, an observational study on mortality and causes of death in patients with polycythemia vera. 

In an interview with Targeted Oncology™, Richard T. Silver, MD, discussed the role of interferon in the treatment of myeloproliferative neoplasm as well as the importance of the 3-year global MPN initiative being conducted by the MPN Research Foundation.

The study is currently recruiting in 5 states and aims to determine if ruxolitinib affects GvHD rates in patients received HSCT for the treatment of myelofibrosis.

Ropeginterferon alfa-2b-njft has been granted FDA approval for the treatment of adults patients with polycythemia vera.